Q-omics provides the consensus-scored SNHG18 profile across patient tissues and cancer cell-line models. SNHG18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNHG18 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SNHG18 RNA expression shows 13,352 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where SNHG18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG18 survival associations across molecular data types. SNHG18 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG18 RNA expression–survival associations across cancer types. High SNHG18 expression shows unfavorable associations in LGG, but favorable associations in UVM, UCS, KIRP, BLCA and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNHG18 RNA expression.
This table summarizes SNHG18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG18 shows lower tumor expression in KICH, THCA, LUAD, LIHC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher SNHG18 RNA expression in tumor versus normal tissue (log2 FC = +1.133, t-test p < 0.001).
This table shows molecular features associated with SNHG18 in patient tissues and cancer cell lines. In patient samples, SNHG18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
